1.1
Ranibizumab, within its marketing authorisation, is recommended as an option for the treatment of wet age-related macular degeneration if:
-
all of the following circumstances apply in the eye to be treated:
-
the best-corrected visual acuity is between 6/12 and 6/96
-
there is no permanent structural damage to the central fovea
-
the lesion size is less than or equal to 12 disc areas in greatest linear dimension
-
there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes) and
-
-
the manufacturers of ranibizumab (branded or biosimilar) only provide it at a discount level no lower than the discount agreed in the patient access scheme.